Remote adult ADHD assessment · Ages 18+ · Northern Ireland

Clear, professional adult ADHD assessment in Northern Ireland.

Carlingford Private Clinic documented a remote assessment pathway for adults aged 18 and over, focused on ADHD assessment, formal diagnosis and diagnostic reporting. Treatment and prescribing were outside the documented service scope.

Information page — availability was being confirmedThis website did not offer online booking or accept clinical records. Visitors were asked to use a brief enquiry to ask what was available.
Priority blockers · launch RAG

RED — the enquiry form is not operational.

This preview is intentionally disabled for live use. Closure requires the controls below; the contact section remains a demonstration only.

  1. Approved secure form service and secure data path.
  2. Clinic-domain mailbox and named owner.
  3. Assessment, general, marketing and partnership routing rules.
  4. Approved privacy notice, lawful basis, retention and processor controls.
  5. Fictional end-to-end test, escalation boundary and accountable sign-off are required before any public release.
Open closure pack
RED

No email, booking, waiting-list place or record upload is created by this prototype.

Current readiness dashboard · 1 October 2026

What is complete, and what is still a launch gate?

This dashboard separates website preparation from evidence-backed operational readiness. It is a local review snapshot, not a claim that the service is approved, open or accepting patients.

Weighted preparation
40%

12/30 launch-register items prepared in the latest recorded baseline. This is not a live synchronised board.

Critical launch gates
0/4

RQIA position, scope-matched indemnity, secure systems and accountable publication approval remain unclosed.

Content and design
72/100

Planning estimate for this prototype’s clarity and traceability; it is not clinical or regulatory readiness.

Operational completion: not launch-ready. The page can be reviewed as a content prototype. It must not accept patient data, payments, bookings or clinical records until the red gates are evidenced and approved.

Source boundary: latest recorded Carlingford launch register (27 September 2026), this prototype’s gap analysis and the linked ACLS records. Recalculate after each verified evidence change.

Local, transparent and clinically responsible.No guaranteed diagnosis, medication, shared care or NHS acceptance.
At a glance

The essentials, without the small print.

Unconfirmed details are deliberately marked rather than guessed. Contact the clinic for the current position.

Who the service was for

Adults aged 18+

The documented service did not include child or adolescent assessment.

Assessment type

Assessment, formal diagnosis and report

Autism and other neurodevelopmental assessments are outside Phase 1.

Appointment format

Remote only in Phase 1

Face-to-face care was outside the documented Phase 1 scope.

Areas served

Northern Ireland

Final eligibility and regulatory acceptance were not confirmed.

Expected waiting time

Contact us for current availability

Assessment price

£1,495 standard fee

Introductory offer: £995 for the first 15 new patients. Pre-launch information only; no deposit or payment is requested on this page.

Report turnaround

Not confirmed

Follow-up options

Feedback and onward recommendations

Final format and responsibility awaited approval; ongoing treatment was not included.

Medication, titration and shared care

Not offered in Phase 1

No prescribing, titration or medication monitoring were included. GP/HSC decisions were separate.

Patient pathway

A clear route from enquiry to next steps.

This was the documented pathway. The final operational process remained subject to approval.

An enquiry was not a diagnosis. Any assessment outcome depended on an individual clinical evaluation and the information available.
01

Initial enquiry

Contact the clinic with basic details only. Do not send medical records through the general enquiry route.

02

Suitability and information review

The documented process required the clinic to confirm whether the service appeared relevant and explain any information needed through an approved secure process.

03

Comprehensive remote ADHD assessment

The ACLS pathway covered adult eligibility, identity and consent, developmental and current history, functional impact, appropriate collateral information, differential formulation and risk. Final templates and testing were pending.

04

Formal diagnostic report and feedback

The documented report covered the clinical conclusion, supporting evidence, uncertainty and recommendations. Final contents, secure delivery and turnaround time remained to be approved.

05

Feedback and onward recommendations

The documented process required recommendations to be discussed individually. Phase 1 did not provide treatment, prescribing, titration or medication monitoring; GP and HSC decisions were separate.

Pre-launch review · 1 October 2026

No bookings, payments or patient records are accepted through this prototype. The proposed standard assessment fee is £1,495, with an introductory £995 offer for the first 15 new patients. Detailed inclusions, payment/cancellation/refund terms, working contact routes and real availability still require approval before publication.

Phase 1 is planned as adult ADHD assessment only. Treatment and prescribing are not included. Before payment, patients must receive confirmed inclusions and onward-care information, including possible additional assessment/costs. NHS prescribing or shared care is not guaranteed.

The existing design estimate is not proof of operational readiness. This is a review-only pre-opening prototype. It must not accept patient data, payments, bookings or clinical records.

Why Carlingford Private Clinic

Clear boundaries, a local focus and a pathway people can follow.

The website has been structured around the facts that matter most to a prospective patient. Verified operational details will be added only after approval and testing.

01 · Scope

Adult ADHD only

A documented Northern Ireland pathway for adults aged 18+, with clear Phase 1 exclusions.

02 · Clarity

Plain-language stages

Enquiry, suitability, assessment, report, feedback and onward recommendations are separated.

03 · Safety

Privacy-minded contact

The prototype asks for minimal information and does not invite clinical records through ordinary email.

04 · Honesty

No invented promises

The proposed price is shown; inclusions, availability, credentials and booking remain unconfirmed until evidenced.

Operational confidence is the next improvement. The content and design are ready for review; live contact, availability, secure systems and launch approval remain outstanding. Pricing inclusions and terms also require approval.
Transparent pricing

One clear total before you decide.

The proposed standard assessment fee is £1,495. The first 15 new patients may be offered an introductory fee of £995. Proposed review appointment options are also shown below. This is pre-launch information only: there is no booking, deposit or payment route.

Offer terms require final approval before opening
Standard assessment fee£1,495
Introductory offer£995 for the first 15 new patients
Proposed 10-minute review appointment£145
Proposed 15-minute review appointment£195
Proposed 25-minute review appointment£295
Written diagnostic reportInclusion to be confirmed before launch
Feedback appointmentInclusion to be confirmed before launch
Deposit and balance timingAwaiting approval — no payment accepted
Cancellation and refund termsTo be published before any booking or payment route opens
Medication and titration were not offered. These proposed review appointment options do not introduce prescribing, titration or medication monitoring, which remain outside the documented Phase 1 service.

Membership concept — educational access

Draft proposal: a £10 monthly membership could provide access to an educational ADHD blog and other clearly listed non-clinical information.

The £995 introductory assessment offer is limited to the first 15 new patients. It is separate from this membership concept and does not require membership.

Not operational: membership would not guarantee an assessment, priority access, diagnosis, clinician availability, treatment, prescribing, titration, shared care or an outcome. No payment or registration is available through this page.

Clinician

Clear clinical responsibility.

The ACLS working record named Dr Moutray as the sole assessing doctor and clinical owner in the documented scope. Draft biography: Dr Moutray’s documented adult ADHD work includes developmental and psychiatric history-taking, assessment, diagnostic formulation and written reporting. Exact biography, role wording and a genuine headshot remain subject to review and publication approval.

Profile approval pending

Dr Paul Moutray

Medical practitioner · proposed assessing doctor and clinical lead

View the public Top Doctors listing ↗External listing; it is not evidence of Carlingford appointment, RQIA approval or current availability.
RegistrationGMC number: 4679419 · recheck before public release
Documented remitRemote adult ADHD assessment and diagnostic reporting
After assessmentFeedback and onward recommendations
Outside Phase 1Treatment, prescribing, autism, CAMHS and face-to-face care
Northern Ireland information

Private assessment and HSC care are separate pathways.

  • Northern Ireland has its own Health and Social Care system and local Trust pathways.
  • NHS England patient-choice guidance, often described as “Right to Choose”, sets out rights under the NHS Constitution for England; it should not be assumed to apply automatically in Northern Ireland.
  • Ask your GP or relevant HSC Trust about local referral options before making decisions about private care.
  • A private diagnosis does not guarantee NHS prescribing or a shared-care arrangement.
  • Any prescribing or shared-care decision remains with the responsible GP and relevant clinical service, applying their own clinical and governance requirements.

Sources: NHS England patient choice guidance; NI Department of Health ADHD Needs Assessment 2026; NI DoH shared-care FOI response.

Frequently asked questions

Twenty straight answers, controlled through ACLS.

These answers use the current central ACLS record. Confirmed scope is stated plainly; draft controls and decisions still awaiting approval are identified rather than filled with figures from older website attempts.

Both self-referrals and referrals from a GP or other appropriate professional are accepted. The clinic will confirm eligibility and whether a remote assessment is suitable before an appointment is arranged. A referral does not guarantee assessment, diagnosis, prescribing, shared care or acceptance by another service.

ACLS defined the assessment components—clinical and developmental history, current symptoms and functioning, relevant health and risk information, collateral information where appropriate, formulation and reporting—but did not contain an approved appointment number or duration. These were to be published before booking opened.

For a general enquiry, provide only basic contact details and a short request for service information. Do not email detailed symptoms, medication history or medical records unless the clinic later provides an approved secure route.

The draft ACLS report standard covers the evidence considered, relevant history and functional impact, clinical formulation, diagnostic conclusion or non-diagnosis, uncertainty and recommendations within the assessment-only scope. The final template and secure-delivery process still require approval.

The documented Phase 1 service was remote-only. Remote suitability, identity, location, consent and any reasonable adjustments were to be checked through the approved pathway. Face-to-face assessment was outside the launch scope.

A non-diagnosis was a valid clinical outcome. The documented pathway included an explanation of the evidence and uncertainty, feedback and appropriate onward recommendations; exact feedback arrangements still required approval.

Acceptance was not guaranteed. Your GP and relevant HSC service made their own clinical and governance decisions about the report and any subsequent care.

The documented assessment-only pathway included feedback, a written report and onward recommendations. It did not include ongoing treatment, prescribing, titration or medication monitoring.

No. Prescribing, medication initiation, titration and medication monitoring were outside the documented Phase 1 service.

The documented Phase 1 clinic did not provide prescribing or titration and could not guarantee shared care. Any GP or HSC prescribing decision was separate and remained with the responsible service.

The ACLS patient-terms record confirmed that no assessment fee, payment timing, cancellation terms or refund terms had been approved. The final total and everything included were to be published together before booking opened; no payment was requested through this page.

Visitors were asked to tell the clinic about communication or access needs in general terms. Remote suitability and reasonable adjustments formed part of the documented pathway, but the approved process was not confirmed.

This static page does not collect or transmit personal information. ACLS requires an approved clinical-record system, individual access with strong authentication, secure patient-portal delivery, an approved privacy notice, processor checks and an approved retention schedule before live collection begins. Those controls are designed but not yet approved or implemented.

Use the clinic contact route for non-urgent concerns. Carlingford Private Clinic is not an emergency or crisis service. If someone is in immediate danger, call 999 or attend the nearest Emergency Department.

No. The clinic was pre-opening and this page did not provide online booking. Availability was to be stated when the service, governance and launch requirements were confirmed.

The documented direction was remote adult ADHD assessment for people aged 18 and over in Northern Ireland. Detailed inclusion, exclusion, geographic and remote-suitability criteria still required final approval.

No. Questionnaires and rating scales could contribute information, but they did not replace a comprehensive clinical assessment or guarantee a diagnosis.

Developmental history and collateral or informant information could be requested where clinically appropriate. The final requirements, alternatives and consent process were to be explained before assessment.

A written report was part of the documented pathway. ACLS designed secure release through an approved patient portal after clinical review and final approval, with delivery recorded. No turnaround promise, portal or delivery process had been approved or made operational; the timescale was to be published before booking opened.

ACLS requires complaints to be fully investigated and answered within the applicable 28-day requirement, with records, learning and escalation. The dedicated contact route and independent escalation arrangement are not yet approved or operational. Until then, the email on this page is only for a brief non-urgent request for information, not a live clinical complaints system.
Trust and governance

Important information in one place.

These are pre-launch summaries, not claims of regulatory approval. Full policies require accountable approval before publication.

Privacy

The page did not collect personal information. A complete privacy notice, retention schedule and secure intake process were to be confirmed.

Safeguarding

The safeguarding policy, named responsibilities and escalation routes require approval before service launch.

Complaints

The complaint route, response times and escalation information were to be confirmed.

Cancellation and refunds

No payment is taken here. Final cancellation and refund terms must accompany approved pricing.

Accessibility and adjustments

Visitors were asked to mention communication or access needs in general terms. The formal reasonable-adjustment process was to be confirmed.

Registration and regulation

The GMC number supplied for Dr Moutray was 4679419; current primary-evidence verification remained part of the pre-opening review. The clinic’s applicable RQIA classification or registration position was not asserted on this page and remained to be confirmed.

Legal operator: Carlingford Private Clinic is a trading name of Future Healthcare (N.I.) Ltd, registered in Northern Ireland, company number NI606918. Registered office: Unit-461 Moat House, 54 Bloomfield Avenue, Belfast, Northern Ireland, BT5 5AD. This is the registered office, not a patient appointment address. Clinical service launch and the applicable RQIA position remain subject to confirmation.

Emergency and crisis-care limitation

Carlingford Private Clinic is not an emergency or crisis service. Do not use this webpage or email for urgent help. If someone is in immediate danger, call 999 or attend the nearest Emergency Department.

Website changelog

What has changed.

This record covers changes to the CPC information page. It is a website record, not evidence of regulatory approval, service launch or clinical activity.

Added a quick-answer assistant

Added a floating assistant with suggested questions about bookings, scope, pricing, medication and Phase 2 CAMHS. It uses only fixed, controlled preview topics; no personal or clinical message is entered or transmitted. The local AI connection is optional and falls back to controlled answers.

Added an AI acknowledgement preview

The enquiry form can now display an automatic acknowledgement based on the selected enquiry category. When the local AI server is configured, only that category is sent to the model. Names, email addresses and messages stay in the browser. No enquiry is submitted or waiting-list place created.

Added a public changelog

Added this section and navigation link so visitors can distinguish current website changes from confirmed service information. Existing unconfirmed details remain labelled as such.

Initial pre-opening information page

Published the documented adult ADHD assessment scope, patient pathway, pricing placeholders, FAQs, governance notes and enquiry-routing demonstration. Booking, payment and clinical-record submission were not enabled.

Current status

Pre-opening information page. Availability, pricing, detailed eligibility and regulatory position still require confirmation before public launch.

Contact

Tell us what you need.

Use the short form to preview an acknowledgement for your enquiry category. Assessment enquiries are marked as priority; marketing and partnership requests are kept separate from clinical enquiries.

Pre-launch prototype: this local form does not send or store an enquiry. Only the selected category is sent to the local AI preview server when it is running. A secure form service and approved mailbox rules are required before any live autoresponder can be used.

Please do not include symptoms, diagnoses, medication history, medical records or urgent concerns. Messages are limited to 200 characters.

Please enter your name.
Please enter a valid email address.
Please choose an enquiry type.
Please enter a brief message.
0/200
ACLS website gap analysis

What the website has — and what it still needs.

This page is cross-checked against the canonical ACLS Carlingford website section, the ACLS import register and the ACLS gap analysis. “Present” means the website contains the documented information; it does not mean that the service is approved or operational.

AreaStatusWebsite / ACLS positionEvidence or next action
Audience and core serviceYESAdults aged 18+ in Northern Ireland; remote ADHD assessment, diagnosis and reporting.Imported from ACLS. Regulatory and launch acceptance remain separate gates.
Scope boundariesYESNo treatment, prescribing, titration, medication monitoring, autism, CAMHS or face-to-face care in Phase 1.Imported from ACLS and displayed in the facts row, pathway and FAQs.
Referral routeYESBoth self-referrals and GP or appropriate professional referrals are accepted.Added 25 September 2026. Eligibility and remote-suitability checks still apply.
Assessment pathwayYESIdentity, consent, developmental/current history, functional impact, collateral where appropriate, differential formulation and risk are described.ACLS identifies final templates, training, implementation and testing as outstanding.
Enquiry safeguardsYESName, email, category and a 200-character message limit; no clinical records through the general route.The prototype does not send or store submissions. A secure live backend is still missing.
Named clinicianPARTIALDr Paul Moutray is named as clinical owner and linked to a public profile.Approved biography, current credentials, role boundaries and publication sign-off remain missing.
Price and inclusionsMISSINGNo approved total assessment fee, inclusions, payment timing, cancellation or refund terms.Owner decision and approved PG01 patient terms required before booking or payment.
Availability and timingMISSINGNo approved wait, appointment availability, assessment duration or report turnaround.Publish only after real capacity and a tested pathway exist.
Contact infrastructureMISSINGNo live clinic-domain email, public telephone route, hours, response owner or voicemail boundary.Configure and test before public enquiries are accepted.
Secure clinical systemMISSINGNo evidenced Cliniko tenant configuration, access roles, secure report delivery or fictional end-to-end test.ACLS records the scenarios, but all operational tests remain outstanding.
Governance and launch authorityMISSINGExact-scope RQIA evidence and final launch sign-off remain open. Personal indemnity issuance is evidenced internally; provider/entity and role-specific cover still require reconciliation.Obtain primary evidence and accountable approval; website wording cannot create approval.
Public policiesPARTIALPrivacy, safeguarding, complaints, cancellation and accessibility summaries are present.Controlled approved versions, owners, effective dates and operational routes remain missing.
Overall website gap status: AMBER/RED. The content and design are substantially documented, but the page is not a live booking service and must not be treated as launch-ready until the missing evidence is closed.

Questions only ACLS cannot answer

  1. What final total assessment price should be published, and exactly what does it include?
  2. What payment, cancellation, refund and additional-fee terms should apply?
  3. What clinic-domain email address and public telephone number should be published?
  4. Who owns telephone and email enquiries, during which hours, and what response time should be promised?
  5. Once approval is granted, what real appointment availability, assessment duration and report turnaround should be published?
  6. Which specific adult eligibility exclusions or remote-unsuitability criteria should be stated publicly?
  7. Which approved clinician biography, photograph, credentials and role wording may be published?
Website changelog

25 September 2026 — Referral routes updated: Both self-referrals and referrals from a GP or other appropriate professional are accepted. Eligibility and remote-suitability checks still apply. This does not promise assessment, diagnosis, prescribing, shared care or acceptance by another service.

Changelog entry · 25 September 2026 · 16:40 BST

Comparator-led website upgrade.

Added a clearer “Why Carlingford” trust panel, a direct link to the ACLS gap analysis, stronger scan-friendly pathway framing and explicit verification boundaries. The website score improves for clarity and traceability, but operational readiness remains unchanged because approved price, availability, contact infrastructure, secure systems and launch gates are still outstanding.

Before
69/100

Comparator benchmark baseline.

After
72/100

Planning estimate after content structure and traceability improvements.

Effect
+3

Clarity, conversion structure and ACLS traceability. Launch RAG remains RED.

Next evidence required: approved fee/inclusions, clinician verification, domain email and telephone, availability, report timing, secure system testing, RQIA position, indemnity and accountable publication approval.